Berliner Boersenzeitung - AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease

EUR -
AED 4.26841
AFN 80.362394
ALL 97.542216
AMD 446.735356
ANG 2.080099
AOA 1065.794205
ARS 1481.767207
AUD 1.776887
AWG 2.092071
AZN 1.980459
BAM 1.954642
BBD 2.348809
BDT 141.226338
BGN 1.956132
BHD 0.43834
BIF 3466.946195
BMD 1.162261
BND 1.493215
BOB 8.038238
BRL 6.486005
BSD 1.163311
BTN 100.147673
BWP 15.618748
BYN 3.807045
BYR 22780.325028
BZD 2.336716
CAD 1.596076
CDF 3354.287055
CHF 0.932981
CLF 0.029194
CLP 1120.296341
CNY 8.342655
CNH 8.346165
COP 4674.330945
CRC 587.052233
CUC 1.162261
CUP 30.799929
CVE 110.199718
CZK 24.634179
DJF 206.947405
DKK 7.463699
DOP 70.258379
DZD 151.514244
EGP 57.439973
ERN 17.433922
ETB 161.636047
FJD 2.620788
FKP 0.864949
GBP 0.86668
GEL 3.150183
GGP 0.864949
GHS 12.127816
GIP 0.864949
GMD 83.106172
GNF 10094.020343
GTQ 8.931709
GYD 243.385819
HKD 9.121487
HNL 30.445964
HRK 7.532663
HTG 152.739518
HUF 398.923459
IDR 18977.696027
ILS 3.908598
IMP 0.864949
INR 100.127437
IQD 1523.897249
IRR 48945.741055
ISK 142.354235
JEP 0.864949
JMD 186.029797
JOD 0.824089
JPY 172.932309
KES 150.300962
KGS 101.640213
KHR 4662.238109
KMF 491.989694
KPW 1046.046309
KRW 1616.942576
KWD 0.355234
KYD 0.969426
KZT 620.152624
LAK 25087.138481
LBP 104232.653
LKR 350.972086
LRD 233.241828
LSL 20.596898
LTL 3.431856
LVL 0.703041
LYD 6.327252
MAD 10.519168
MDL 19.788278
MGA 5176.933206
MKD 61.523554
MMK 2439.678938
MNT 4168.013035
MOP 9.404829
MRU 46.275587
MUR 53.119698
MVR 17.903172
MWK 2017.205016
MXN 21.777182
MYR 4.935007
MZN 74.338683
NAD 20.596898
NGN 1779.387897
NIO 42.814637
NOK 11.838157
NPR 160.236077
NZD 1.94976
OMR 0.446995
PAB 1.163311
PEN 4.140847
PGK 4.817146
PHP 66.377189
PKR 331.310933
PLN 4.244785
PYG 9003.666265
QAR 4.229694
RON 5.072695
RSD 117.080642
RUB 91.375869
RWF 1681.00418
SAR 4.36165
SBD 9.64543
SCR 17.082281
SDG 697.942292
SEK 11.245095
SGD 1.492813
SHP 0.913355
SLE 26.62005
SLL 24372.046713
SOS 664.806172
SRD 43.245469
STD 24056.466061
STN 24.485495
SVC 10.17897
SYP 15112.803405
SZL 20.592801
THB 37.628259
TJS 11.196867
TMT 4.079538
TND 3.419874
TOP 2.722137
TRY 46.947496
TTD 7.897322
TWD 34.181766
TZS 3030.404801
UAH 48.58252
UGX 4168.530579
USD 1.162261
UYU 46.882227
UZS 14725.276806
VES 135.943958
VND 30404.760344
VUV 138.92149
WST 3.080055
XAF 655.568644
XAG 0.030448
XAU 0.000347
XCD 3.14107
XCG 2.096558
XDR 0.815317
XOF 655.568644
XPF 119.331742
YER 280.163552
ZAR 20.586499
ZMK 10461.752209
ZMW 26.785133
ZWL 374.247723
  • CMSC

    0.0900

    22.314

    +0.4%

  • CMSD

    0.0250

    22.285

    +0.11%

  • RBGPF

    0.0000

    69.04

    0%

  • SCS

    0.0400

    10.74

    +0.37%

  • RELX

    0.0300

    53

    +0.06%

  • RIO

    -0.1400

    59.33

    -0.24%

  • GSK

    0.1300

    41.45

    +0.31%

  • NGG

    0.2700

    71.48

    +0.38%

  • BP

    0.1750

    30.4

    +0.58%

  • BTI

    0.7150

    48.215

    +1.48%

  • BCC

    0.7900

    91.02

    +0.87%

  • JRI

    0.0200

    13.13

    +0.15%

  • VOD

    0.0100

    9.85

    +0.1%

  • BCE

    -0.0600

    22.445

    -0.27%

  • RYCEF

    0.1000

    12

    +0.83%

  • AZN

    -0.1200

    73.71

    -0.16%

AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease
AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease

AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease

  • Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin

  • Lead indication is non-CF bronchiectasis; ATL-105 targets disease drivers through a broad multimodal mechanism of action

Text size:

VILNIUS, LT / ACCESS Newswire / July 15, 2025 / AATec Medical GmbH ("AATec"), a biotech company developing a multi-product platform for the treatment of respiratory diseases, and Northway Biotech ("Northway Biotech" or "NBT"), a global Contract Development and Manufacturing Organization (CDMO), today announced a partnership for manufacturing process development and analytical development of AATec's lead product candidate, ATL-105, a proprietary, inhaled therapy based on recombinant alpha-1 antitrypsin (AAT) for non-cystic fibrosis bronchiectasis (NCFB).

AATec Medical and Northway Biotech Announce Partnership

Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop and scale the production process for ATL-105 using the Pichia pastoris expression system.

"With this partnership, we are establishing a robust and scalable production process for ATL- 105, laying the foundation for consistent quality for clinical development and commercial use," says Rüdiger Jankowsky, PhD, co-founder and CEO of AATec, and adds: "ATL-105 represents a new generation of inhaled biologics, combining anti-protease, anti-inflammatory, and antiinfective properties in one molecule. Delivered directly to the lungs, it enables fast, targeted action with minimal systemic exposure. We believe ATL-105 can redefine care in respiratory diseases with high medical need, such as non-CF bronchiectasis."

"We are excited to support AATec in progressing towards clinical trials", shares Prof. Vladas Algirdas Bumelis, CEO and Chairman of Northway Biotech. "AATec is advancing a promising therapeutic solution addressing significant unmet medical needs, supported by a highly capable and dedicated team. With our decades of expertise in microbial systems, we are well-positioned to scale this program efficiently and deliver quality at every step."

"We have recognized the opportunity to support a program that could meaningfully advance care for patients with respiratory diseases," adds André Markmann, PhD, VP of Business Development at Northway Biotech. "Inhaled protein therapies are gaining significant traction, and ATL-105 stands out as one of the most promising approaches in this area."

AATec develops ATL-105 to treat NCFB, a chronic inflammatory respiratory condition which affects millions of people worldwide. This debilitating disease is marked by dilated bronchi, persistent inflammation, frequent airway infections and impaired mucus clearance. In addition to NCFB, ATL-105 has therapeutic potential for a broader range of inflammatory and infectious respiratory diseases, such as COPD, ARDS and other indications, reflecting the versatility of its anti-inflammatory, immunomodulatory, and anti-infective properties.

About AATec Medical

AG AATec Medical GmbH is a biotechnology company developing a product platform based on a novel recombinant version of alpha-1 antitrypsin (AAT) for the treatment of respiratory inflammatory diseases, airway infections and rare diseases. The company has successfully demonstrated proof-of-principle in several indications and is currently preparing for a proof-ofconcept clinical trial with the first product candidate ATL-105 for inhaled application in non-CF bronchiectasis. AATec was founded by a seasoned interdisciplinary team with long-standing experience in clinical research, biopharmaceutical development and product industrialization. For further information, please visit https://www.aatec-medical.com/ and follow AATec on LinkedIn.

About Northway Biotech

Northway Biotech is a leading CDMO specializing in protein-based biologics and gene therapies, offering comprehensive, end-to-end biopharmaceutical development and manufacturing services. With deep expertise in cell line development, process optimization, and cGMP manufacturing, Northway Biotech supports programs from early-stage development through to commercial production. Founded in 2004, the privately held company operates state-of-the-art facilities in Lithuania and the United States, delivering high-quality, compliant solutions tailored to each client's unique needs. For further information, please visit https://www.northwaybiotech.com.

Northway Biotech Contact:

Prof. Vladas Algirdas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com

AATec Medical Contact:

Dr. Rüdiger Jankowsky, CEO
info@aatec-medical.com

Media Contact:

MC Services
Katja Arnold, Julia von Hummel
aatec-medical@mc-services.eu
Phone: +49 (0)89 2102280

SOURCE: Northway Biotech



View the original press release on ACCESS Newswire

(T.Renner--BBZ)